586. Immunogenicity of COVID-19 mRNA Vaccines in Patients with Lymphoid Malignancies

BACKGROUND: Patients with lymphoid malignancies are at high risk of severe COVID-19 disease and were not included in the phase 3 mRNA vaccine trials. Many patients with lymphoid malignancies receive immunosuppressive therapies, including B-cell depleting agents, that may negatively impact humoral re...

Descripción completa

Detalles Bibliográficos
Autores principales: Izaguirre, Natalie E, Sherman, Amy C, Crombie, Jennifer, Desjardins, Michaël, Cheng, Chi-An, Gilboa, Tal, Powell, Megan, Bausk, Bruce P, Abasciano, Noah, Baker, Peter, McDonough, Mikaela, Armand, Philippe, Walt, David, Issa, Nicolas C, Baden, Lindsey R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644561/
http://dx.doi.org/10.1093/ofid/ofab466.784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644561/
http://dx.doi.org/10.1093/ofid/ofab466.784

Ejemplares similares